NKMAX, a Korean natural killer (NK) cell-based immunotherapy company, announced on Wednesday that its U.S. subsidiary, NKGen Biotech, has received U.S. FDA approval to initiate phase 1/2a clinical trials for SNK01, an NK cell therapy for Alzheimer’s disease in the U.S.Building on the results of the
The Ministry of Food and Drug Safety said it imposed an administrative penalty equivalent to a one-month suspension of clinical trials on Sanofi Pasteur Korea for the violation of labeling requirements in their ongoing meningococcal conjugate vaccine study.As a result of the violation of the Pharmac
MADRID -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- A Korean company was honored with the title of "Best Poster" at the European Society for Medical Oncology Annual Meeting (ESMO 2023), the largest cancer society in Europe and one of the top three cancer societies in the world.Curoce
BARCELONA, Spain -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- CPHI Worldwide 2023 kicked off for a three-day run at the Fira Barcelona Gran Via convention center in Barcelona, Spain, on Tuesday.CPHI (Convention on Pharmaceutical Ingredients) is the world's largest pharma and bio exhi
JW Pharmaceutical, a Korean pharmaceutical company, said on Wednesday it signed a research agreement with Theraject Asia, a microneedle R&D company, to develop a microneedle-based hair loss treatment.Under the agreement, JW Pharmaceutical's Drug Research Center will utilize Theraject Asia's advanced
Iksuda Therapeutics (Iksuda), a U.K.-based developer of antibody-drug conjugates (ADCs), has successfully completed the first cycle of therapy with IKS014 in the first patient enrolled in a phase 1 study aimed at treating advanced HER2-positive solid tumors.This information was provided by the compa
MADRID -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- The combination of Yuhan's Leclaza (lazertinib) and Janssen's Rybrevant (amivantamab) has been unveiled at the just-ended European Society for Medical Oncology (ESMO) 2023, Europe's largest cancer congress.On Monday, the results fro
Hanmi Pharm said the Ministry of Food and Drug Safety (MFDS) has approved its phase 3 clinical trial plan for efpeglenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, to treat obesity.After submitting an investigational new drug (IND) application to the MFDS in July, Hanmi was able to secu
MADRID -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- An enthusiastic standing ovation erupted in the Madrid Hall of the Ipema Convention Center, home to the European Society for Medical Oncology's Annual Meeting (ESMO 2023) in this Spanish capital city, on Wednesday.That occurred when
VaxCell-Bio, a Korean biotech company, said it has applied for product authorization with the Animal and Plant Quarantine Agency for Vaxleukin-15, which aims to become "the world's first immunotherapy exclusively for dogs."The company submitted the application after conducting clinical trials in 42
Janssen Korea, committed to innovation to stay ahead of diseases, pledged growth through cooperation with various stakeholders during a press conference celebrating its 40th anniversary on Monday.Established in 1983 as the Korean subsidiary of Johnson & Johnson's pharmaceutical division, Janssen Kor
SK bioscience said it has applied for emergency use authorization (EUA) for the improved Novavax’s Covid-19 vaccine (NVX-CoV2601), with the Ministry of Food and Drug Safety(MFDS).The updated Novavax Covid-19 vaccine received EUA from the U.S. Food and Drug Administration (FDA) for active immunizatio
MADRID -- By Kim Chan-hyuk Korea Biomedical Review correspondent -- The curtain has risen on the European Society for Medical Oncology's Annual Congress (ESMO 2023) at the IFEMA Convention Center in Madrid.ESMO is the largest cancer society in Europe and one of the top three cancer societies in the
JW Pharmaceutical said last Friday it had received notification from LEO Pharma of its intention to return the rights for LEO 152020, a substance aimed at treating atopic dermatitis. LEO 152020 is also known as JW 1601 in Korea. LEO Pharma, a multinational pharma based in Denmark, returned the right
Korean pharmaceutical companies are preparing to have a significant impact at this year's CPhI 2023 event, taking place in Barcelona, Spain, from Oct. 24 to 26.CPhI, the world's largest pharma-bio event, annually travels to major European countries. It serves as a crucial platform for global busines
Geo-Young, South Korea's largest pharmaceutical distributor, has categorically denied recent speculations about a possible acquisition by Zuellig Pharma, as reported by multiple news sources.Geo-Young refuted rumors suggesting that Zuellig Pharma may be seeking to purchase the company from Blackston
Gilead recently launched the first Trop-2-targeted antibody-drug conjugate (ADC), Trodelvy (sacituzumab govitecan), in Korea, providing a new treatment option for patients with metastatic triple-negative breast cancer who have limited options.Gilead began the domestic supply of Trodelvy on Wednesday
AstraZeneca's Soliris (eculizumab) has demonstrated its long-term efficacy and safety profile in a real-world study in Korean patients with paroxysmal nocturnal hemoglobinuria (PNH).The October issue of the Journal of Korean Medical Science, an international medical journal of the Korean Medical Ass
The nation's antitrust watchdog has slapped JW Pharmaceutical with a correction order and a hefty fine of 29.8 billion won ($21.9 million) for providing widespread illegal rebates to over 1,500 hospitals and clinics nationwide.This fine represents the largest ever imposed in a pharmaceutical rebate
ATGC, a Korean manufacturer of botulinum toxin (BTX), said it entered into a strategic collaboration and licensing agreement with Huadong Medicine Aesthetics Investment Limited, the parent company of Sinclair Pharma Limited, an aesthetic company based out of London, for ATGC-110, the ATGC's botulinu